human atrial and ventricular myocardial preparations.11 However, A,-adenosine receptor-coupled functional responses have not been examined in failing versus nonfailing human heart.
Despite these numerous studies, the roles of adenosine and adenosine receptors are not well understood in cardiac muscle physiology. 16 Based on the degree of negative inotropic effect produced by Aladenosine receptor activation and the amount of adenosine present in cardiac tissue, it is conceivable that the A,-adenosine receptor pathway may maintain some basal or tonic negative inotropic influence in working myocardium. '6 Although the kinetics of adenosine production and degradation are not known in failing human heart, cardiac adenosine release has been observed to be increased threefold in a canine model of heart failure.17 Whether such changes imply increased cardiac A,-adenosine receptor pathway activation is unknown.
The present study is based on the hypothesis that cardiac adenosine may play some role in inotropic control of failing human ventricular myocardium, particularly as the G protein to which the A,-adenosine receptor is coupled, Gi, is increased in activity in the failing human heart. Recent examinations of G proteins in failing human heart have demonstrated a 30-40% increase in a 40,000-MW pertussis toxinsensitive substrate18-20 subsequently shown to be aGi3,2l with decreased adenylate cyclase activity in failing human heart consistent with increased inhibitory G protein (Gi) activity. '8,22 Therefore, it is possible that a Gi-coupled receptor pathway such as the A,-adenosine receptor may have augmented signal transduction related to the increase in aGi.
The purpose of the present study was to examine A,-adenosine receptor-mediated inhibition of adenylate cyclase in preparations of human ventricular myocardium and to compare these adenylate cyclase responses in failing and nonfailing human heart. Methods 
Tissue Procurement
Human cardiac tissue was obtained from the Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program. Twelve failing hearts were explanted from patients undergoing orthotopic heart transplant operations, and 10 nonfailing hearts were received from kidney donors whose hearts were not used for transplantation because of late developing recipient exclusions, recipient blood type or size mismatch, or age (n=2). In all cases, repeated attempts were made to place these hearts for organ donation using the United Network for Organ Sharing.
Failing hearts were from 10 men and two women (mean age, 39 years) with idiopathic dilated cardiomyopathy and chronic end-stage congestive heart failure. Mean cardiac index was 1.9+±0.14 1/min/m2; mean pulmonary wedge pressure was 24.9±1.5 mm Hg; and mean ejection fraction was 17.3±1.9%. All patients were taking vasodilators, digoxin, and diuretics. Nonfailing hearts were from eight men and two women (average age, 30 years). The 10 donor hearts had normal cardiac function by history and echocardiography. Two additional nonfailing left ventricles were received from patients with primary pulmonary hypertension who were undergoing heart and lung transplant with well-preserved left ventricular function by clinical, echocardiographic, and biochemical indexes.
Immediately after cardiectomy, hearts were placed into iced saline slush and then transported to the laboratory in ice-cold physiological salt solution. All 12 failing hearts and nine of 12 nonfailing hearts or left ventricles were procured locally, with less than 30 minutes between explantation to arrival in the laboratory. The three distantly procured donor hearts had cold ischemic times of 1, 1/2, and 2 hours, with adenylate cyclase measurements that did not differ from those of locally procured donor hearts or left ventricles.
Myocardial Membrane Preparations
A preparation suitable for measuring hormonestimulated adenylate cyclase was prepared as previously described.' Briefly, 2 g of ventricular myocardium was trimmed free of endocardium and epicardium and placed into a sucrose (250 mM), Tris (10 mM), and EGTA (1 mM) buffer (pH 7.5). Myocardium was homogenized three times for 3 seconds each time with a polytron at full speed. The homogenate was centrifuged at 1,200g for 20 minutes, and the pellet was resuspended with a loosely fitting motorized pestle. After two additional centrifugations, the final pellet was resuspended in 12 ml sucrose-Tris-EGTA buffer and filtered through gauze into a glass homogenizer. After 20 passes with a closely fitting nylon pestle, the preparation (final protein concentration, 6-10 mg/ml) was stored at -800C.
A crude membrane preparation suitable for measuring a-receptors was made as previously described.2 Briefly, ventricular myocardium was homogenized, after which contractile proteins were extracted in 0.5 M KCl. The homogenate was centrifuged at 50,000g and resuspended three times, with the final resuspension in high sucrose-Tris buffer. The preparation was frozen at -80°C until use.
The time between preparation of tissue and use for biochemical determinations ranged from 3 to 15 months, with preparation storage time matched between groups. We have been unable to demonstrate degradation of adenylate cyclase activity or receptor densities with storage times of more than 24 months under these conditions (unpublished data).
Biochemical Determinations
Adenylate cyclase assays were performed as previously described.13 For routine assay, a reaction mixture was made consisting of 100 mM Tris (pH 7.30 at 30°C), 10 mM phosphocreatine, and 0.1 mM Mg . ATP with 0.5 mM or 2.5 mM in excess MgC12, 10 gtm GTP, 1 mM cAMP, 1.75 units creatine kinase per assay tube, 0.3 units adenosine deaminase per assay tube, 1 ,M propranolol, and a trace label of 3H cAMP (10,000-12,000 cpm per tube). Agonists of choice as well as reaction mixture and 0.05-0.125 mg of myocardial preparation were added to tubes, all of which were preincubated at 30°C for 10 minutes, after which a trace label of a-32P-ATP was added (800,000-1 million cpm per tube) in a final volume of 250 ,l. After an additional 20-minute incubation at 300C, 750 ,ul of 1% sodium dodecyl sulfate was added to stop the reaction, and reaction products were separated according to the two-column method of Salomon et al. 23 Column recovery was routinely 70-90%. Protein concentrations were determined after the method of Lowry et al. 24 To examine changing magnesium or substrate concentrations, substrate was held constant at 0.1 mM Mg . ATP or 0.5 mM Mg, respectively. For substrate kinetic studies, Mg. ATP concentrations ranging from 0.025 to 0.4 mM with 0.5 mM MgCl2 in excess were used. For each concentration of substrate, water (basal determination), 0.3 ,M and 0.1 mM isoproterenol, and 0.1 and 10 ,uM R-phenylisopropyladenosine (R-PIA) were added in duplicate tubes. Magnesium kinetics were performed with magnesium ranging from 0.25 to 5.0 mM. All kinetic data were converted to "s-multiplied" double-reciprocal linear plots (Hane's plots25); substrate dissociation constant (KD) and Vm., and magnesium Ka and Vma. were then calculated as previously described.3
For experiments to examine 13-receptor effects on adenylate cyclase activity, propranolol was omitted and Mg was 0.5 mM in excess, with adenosine deaminase either present or absent.
[3-Receptor Measurements
Saturation binding assays to measure 13-receptor density and affinity were conducted with '1I-cyanopindolol (1`ICYP), as previously described.2 Specific binding routinely exceeded 90%. Protein concentrations of receptor-binding preparations were determined by the Peterson modification of the Lowry method. 26 
ADP-Ribosylation
Pertussis toxin-sensitive G proteins were estimated in the crude particulate (adenylate cyclase) preparations as previously described. 21 
Data and Statistical Analyses
Adenylate cyclase data points were means of duplicates, except for time course studies that were means of triplicates, and expressed as picomoles of cAMP produced per minute per milligram of added membrane protein. As previously described,12 doseresponse curves were modeled with nonlinear leastsquares computer-assisted curve fitting to a fourparameter logistic equation of DeLean et a127 to find the best fit of a sigmoidal curve, including minimum, maximum, ED50, and slope. ,B-Receptor density (Bm.) and KD were found by nonlinear modeling, as previously described.2
For comparing differences between groups, a nonpaired Student's t test was used, with a probability value of less than 0.05 in the two-tailed distribution considered significant. Dose-response curves were compared using an analysis of covariance technique as previously described.2 In comparison of data in more than two groups, analysis of variance and the Bonferroni t test with multiple comparisons28 were used.
Results

Assay Characterization
Adenosine deaminase. Increasing concentrations of adenosine deaminase progressively increased adenylate cyclase activity with a maximal effect at 0.3 units adenosine deaminase per tube (1.2 units/ml). Adenylate cyclase basal activity was increased approximately 80% with 0.3 units of adenosine deaminase (6.9+ 1.1 versus 12.6±2.1 pmol cAMP/min/mg, n=3). With the addition of the A,-adenosine receptor agonist R-PIA, adenylate cyclase activity was similar to basal activity in the absence of adenosine deaminase. Furthermore, the addition of R-PIA without adenosine deaminase present produced virtually no change in adenylate cyclase activity (data not shown).
Time course and protein concentration effects. Time course effects were evaluated in three experiments and demonstrated linear activation of adenylate cyclase with 0.3 units of adenosine deaminase per tube after the first 5 minutes for the duration of the experiment. Adenylate cyclase activation was linear with protein concentration ranging from 0.1 to 0.8 mg/ml (0.03-0.20 mg per tube) with adenosine deaminase alone and in the presence of R-PIA in four experiments. Approximately 0.4 mg/ml (0.10 mg protein per tube) was used for standard assay conditions.
Guanine nucleotide effects. Adenylate cyclase activity increased with increasing GTP and was maximal with 2-10 ,M GTP; R-PIA-inhibited adenylate cyclase inhibition was also maximal in this range. R-PIA-mediated adenylate cyclase inhibition was not observed in the absence of GTP. For standard assay conditions, 10 ,M GTP was used.
Magnesium and substrate effects. Increasing magnesium concentration substantially augmented basal adenylate cyclase activity. When taken as a fraction of basal activity, maximal R-PIA-mediated inhibition of adenylate cyclase activity occurred with from 2 to 3 mM MgCl2; therefore, 2.5 mM MgCl2 was used for A1-adenosine receptor experiments. In contrast, the greatest ratio of isoproterenol-stimulated adenylate cyclase activity to basal activity was present with 0.5 mM MgCl2, which was used for 13-receptor experiments. This ratio diminished as magnesium increased.
Examination of substrate kinetics demonstrated that Vm.. increased for isoproterenol but not for R-PIA ( Table 1) . Examination of magnesium kinetics demonstrated that the magnesium Ka was substantially decreased for isoproterenol but only minimally (Table 1) . Summary of adenylate cyclase assay conditions. Three assay conditions have been used in the present study to examine different components of the receptor-G protein-adenylate cyclase system. The initial conditions described in earlier re-ports1,3,29 were chosen for the maximal GQ-coupled receptor-stimulated response because they give the greatest degree of stimulation relative to basal activity. In the present study, this condition is called the "stimulatory receptor (GQ) condition" (Table   2 ). However, the optimal condition to observe Gi-coupled receptor inhibition of adenylate cyclase differs from this and is called the "inhibitory receptor (G1) condition" ( Table 2 ). We also previously described optimal conditions to examine G protein effects on adenylate cyclase activity,'S herein called the "G protein condition" (Table 2 ), in which the reaction mixture has no added guanine nucleotides.
A1-Adenosine Receptor Characterization: R-Phenylisopropyl-Adenosine and N-Ethyl Adenosine-5'-Uronamide Effects on Adenylate Cyclase Activity
The adenosine receptor has been categorized into Aland A2-subtypes. 30, 31 In an effort to detect any stimulatory A2-adenosine receptors,3' the effects of increasing concentration of N-ethyl adenosine-5'uronamide (NECA), a high-affinity A2-adenosine receptor agonist,30,31 were examined (Figure 1 ) with stimulatory G, receptor conditions. Adenylate cyclase activity was inhibited with NECA, and the dose-response curve was shifted to the right of an R-PIA dose-response curve by approximately sevenfold, in agreement with the affinity of NECA for the A1-adenosine receptor.30
A1-Adenosine-and /-Receptor-Mediated Adenylate Cyclase Responses in Failing and Nonfailing
Human Heart A1-Adenosine receptor--nediated adenylate cyclase inhibition. The effects of R-PIA on adenylate cyclase LOG ER-PIR/NECRA inhibition were examined in particulate preparations derived from 12 failing and 12 nonfailing hearts with the Gi receptor adenylate cyclase assay condition ( Table 2 ). No differences were present between preparations derived from failing and nonfailing heart for R-PIA-mediated inhibition of adenylate cyclase activity or for ED50s or slopes (Figure 2 ). With identical conditions except for 0.5 instead of 2.5 mM Mg2e, again no differences were present between preparations from nonfailing and failing heart (Table 3) .
(-Receptor adenylate cyclase activation and (-receptor density. ,8-Receptor activation of adenylate cyclase was examined with assay conditions as previously reported (G, receptor assay condition).1,29 Isoproterenol-mediated adenylate cyclase activity was decreased in preparations derived from failing human ventricular myocardium ( Figure 2 adenosine deaminase; therefore, these earlier stud-ies129 were performed with full activation of the A1-adenosine receptor pathway. We evaluated the effects of adenosine deaminase on isoproterenolstimulated adenylate cyclase activity. Adenosine deaminase increased basal adenylate cyclase activity and remained additive to the isoproterenol-activated adenylate cyclase activity (Figure 3 (Table 2 ). With conditions designed to measure G protein effects, basal adenylate cyclase activity was decreased in preparations of failing heart (Table 4 ).
Fluoride-(10 mM), forskolin-(0.1 mM), and manganese-(1 mM) stimulated adenylate cyclase activities were not different in failing versus nonfailing heart with Gi receptor conditions (Table 4 ).
Pertussis toxin-catalyzed ADP-ribosylation was performed in preparations derived from six nonfailing and six failing left ventricles. Pertussis toxin-sensitive autoradiographic bands of 40,000 MW were increased in failing heart (Table 4 ). These 40,000-MW bands colocalized with a pertussis toxin-sensitive substrate from human erythrocyte and have been shown to comigrate with immunochemically detectable aG1.21
Discussion
The present study is the first to examine the coupling of an adenylate cyclase-associated inhibi- In agreement with one recent report,11 results from the present study suggest that adenosine receptors in human ventricular myocardium appear to be a homogenous population consistent with an A,-adenosine receptor subtype known to inhibit adenylate cyclase.30'31 A dose-response curve performed with NECA, an A2-adenosine receptor agonist, yielded only adenylate cyclase inhibition and a right-shifted dose-response curve consistent with NECA effects at an A1-adenosine receptor.30 '31 Experimental conditions were optimized to observe maximal A1-adenosine receptor-mediated adenylate cyclase inhibition in particulate preparations FIGURE 3 . Plots of isoproterenol doseresponse curves performned with standard stimulatory G protein assay conditions not in the presence of adenosine deaminase with preparations derived from six nonfailing (n) and six failing (o) hearts. All results are given as nonfailing versus failing: minima. 10 of human ventricular myocardium. It was necessary to remove adenosine present in our preparations with adenosine deaminase to observe inhibition by A1-adenosine receptor agonists. Concentrations of Mg (2.5 mM) and guanine nucleotides (GTP 10 ptM) were also optimized for maximal adenylate cyclase inhibition. Formal examination of magnesium kinetics for A,-adenosine receptor-mediated adenylate cyclase inhibition suggested that magnesium Vmax was decreased with receptor activation.
Results from the present study indicate that the A,-adenosine receptor pathway was not altered in failing human heart. In particulate preparations derived from 12 end-stage failing left ventricles explanted at the time of cardiac transplantation, adenylate cyclase inhibition mediated by the Aladenosine receptor agonist R-PIA was not different compared with that in control preparations from nonfailing left ventricles. The respective ED50s and slopes of mean dose-response curves were also similar. In contrast, maximal isoproterenol-stimulated adenylate cyclase activity and total ,B-adrenergic receptor density were decreased in failing heart, in agreement with previous reports.1 "2,30 Perhaps the most interesting observation of the present study is the lack of differential inhibition of adenylate cyclase activity in failing versus nonfailing heart by the A,-adenosine receptor pathway. In view of the recently described 30-40% increases in a 40,000-MW pertussis toxin-sensitive substrate termed aG40 in failing human heart,'8-20 subsequently demonstrated to be immunoreactive to antisera for aGi3,2l it might be expected that A,-adenosine receptor-mediated inhibition of adenylate cyclase would be accentuated in failing heart. In our earlier report,18 adenylate cyclase activity was de-creased in failing human heart when guanine nucleotide was not present in the assay (termed "G protein assay condition" in the present study). In the present study with the same (no guanine nucleotide) assay condition, decreased adenylate cyclase activity was also observed in failing heart. In addition, a 40,000-MW pertussis toxin-sensitive substrate was increased by approximately 30%, also in agreement with our previous report.'8 Therefore, both ADPribosylation and adenylate cyclase data support the contention that an inhibitory G protein had increased activity in failing human heart. However, with assay conditions carefully designed to observe maximal receptor-mediated adenylate cyclase inhibition, in the present study termed "inhibitory receptor (Gi) assay condition," the A1-adenosine receptor pathway in failing human heart was not different from that in nonfailing controls. With a modified assay condition (0.5 mM MgCl2) similar to the GS condition, again no difference was observed. In summary, even though aGi was increased in failing human ventricular myocardium, the Gi-coupled Aladenosine receptor pathway did not show enhanced inhibition of adenylate cyclase under two different experimental conditions.
With increased Gi activity identified by pertussis toxin-sensitive ADP-ribosylation, the most straightforward explanation for a lack of increased adenylate cyclase inhibition by the A,-adenosine receptor pathway is that the species of increased Gi may couple poorly to the A,-adenosine receptor, and therefore enhanced A,-adenosine responses will not be observed.32 An alternative explanation is that the decreased A,-adenosine receptor density combined with increased Gi in failing heart may have functionally canceled one another, a possibility that awaits adenosine receptor density measurements. Although radiolabeled ligands are available that have a high affinity and adequate activity in enriched membranes prepared in large quantities of bovine heart, we have not been able to reliably and reproducibly measure A1-adenosine receptor binding in crude membrane preparations available from human heart.
Another possibility is that the presence of 10 mM GTP might shift the ratio of aGi fl3 y heterotrimer to dissociated aGi in the cardiac membranes. If both the increased functional capacity of aGi and the increased pertussis toxin-sensitive substrate in the failing human heart resulted from a greater proportion of aGi being in the bound than in the dissociated state, then the addition of 10 ,tM exogenous GTP to membranes derived from both control and failing heart might shift the dissociation kinetics so that no difference could be seen between the two groups. 33 Finally, the A1-adenosine receptor has demonstrated receptor reserve,34 which if present in the present study could make it difficult to identify alterations in receptor-coupled adenylate cyclase inhibition.
The present study raises one additional question about previous research with GQ-coupled receptors in myocardial preparations. Results from the present study indicate that unless adenosine deaminase is added to the adenylate cyclase reaction mixture, the A1-adenosine receptor is fully activated by adenosine present in the myocardial preparations. We previously reported that /3-receptor-stimulated adenylate cyclase activity is subsensitive in failing heart. 1, 18, 29 In these reports, adenosine deaminase was not used, and therefore the A1-adenosine receptor pathway was fully activated. To examine the A1-adenosine receptor effects on 83-adrenergic receptor adenylate cyclase activation, isoproterenol dose-response curves were performed in the presence and absence of adenosine deaminase. The two sets of isoproterenol dose-response curves were similar, except that the increased basal adenylate cyclase activity noted in the presence of adenosine deaminase appeared to be additive to the isoproterenol responses obtained without adenosine deaminase (Figure 3 ). In addition, the mean isoproterenol dose-response curve performed in failing heart in the presence of adenosine deaminase exceeded the response in nonfailing heart without adenosine deaminase. This suggests that adenosine antagonism might increase some of the /3-adrenergic receptor-mediated subsensitivity present in failing human heart. In summary, adenylate cyclase activity in preparations of human ventricular myocardium is substantially inhibited by A1-adenosine receptor pathway activation. Although functional changes in adenylate cyclase activation are present, consistent with increased Gi in failing human heart,18 no A1-adenosine receptor-coupled difference was observed in failing heart.
